702O Cabozantinib (C) in combination with atezolizumab (A) as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from the COSMIC-021 study
Sumanta K. Pal, C-K. Tsao, Cristina Suárez, William Kevin Kelly, Lance C. Pagliaro, Ulka N. Vaishampayan, Yohann Loriot, S. Srinivas, Bradley A. McGregor, A. Panneerselvam, Desmond Curran, Toni K. Choueiri, Neeraj Agarwal
Topics & Concepts
MedicineAtezolizumabClinical endpointInternal medicineRenal cell carcinomaCabozantinibOncologyClear cell renal cell carcinomaNephrectomyUrologyNivolumabGastroenterologyCancerClinical trialImmunotherapyKidneyRenal cell carcinoma treatmentRenal and related cancersCancer Genomics and Diagnostics